Results 191 to 200 of about 451,686 (317)
Comparative Profiling of microRNA Expression in Soybean Seeds from Genetically Modified Plants and their Near-Isogenic Parental Lines. [PDF]
Wang Y+6 more
europepmc +1 more source
Guidance on the Post-Market Environmental Monitoring (PMEM) of genetically modified plants
openalex +1 more source
The rs10191329 Risk Allele Is Associated With Pronounced Retinal Layer Atrophy in Multiple Sclerosis
ABSTRACT Objective To investigate whether the rs10191329 risk allele in the DYSF–ZNF638 locus, which is implicated in central nervous system resilience rather than immune‐mediated pathology, is associated with retinal layer thinning, a biomarker of neuroaxonal damage in relapsing multiple sclerosis (RMS). Methods From a prospective observational study,
Gabriel Bsteh+22 more
wiley +1 more source
As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox+3 more
wiley +1 more source
Production Of Hydroxylated Fatty Acids In Genetically Modified Plants
David R Hall, Joe Fox
openalex +1 more source
Pollen from genetically modified plants in honey – problems with quantification and proper labelling
Ewelina Żmijewska+3 more
openalex +1 more source
Objective Social determinants of health (SDoH) can impact outcomes but are not routinely screened for in US outpatient rheumatology clinics. This study determined the feasibility of routine point‐of‐care SDoH screening among patients with systemic lupus erythematosus (SLE) and associated barriers and facilitators at the physician, care team, and ...
S. Sam Lim+11 more
wiley +1 more source
Objective This study examined the global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis (OA) burden from 1990 to 2021. Methods Age‐standardized years lived with disability rate for site‐specific OA across 204 countries/territories were obtained from the Global Burden of Diseases Study (GBD) 2021.
Haowei Chen+14 more
wiley +1 more source
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry+16 more
wiley +1 more source